Preliminary updated results of a phase I/II trial using trimodality therapy in patients with post-prostatectomy high-risk pathologic (p) T2-3N0M0 prostate cancer.
Parvesh Kumar
No relevant relationships to disclose
Peter J. Van Veldhuizen
No relevant relationships to disclose
Mark Thompson
No relevant relationships to disclose
Xinglei Shen
No relevant relationships to disclose
James Coster
No relevant relationships to disclose
Jacek Pinski
No relevant relationships to disclose